Cardiac Valve Prostheses: Pathological and Bioengineering Considerations

Journal of Cardiac Surgery

Volumn 2, Issue 1, 1987, Pages 65-108

  SCHOEN, FREDERICK J ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

cardiac pathology; valve prosthesis; valve replacement

Indexed keywords

CARDIOVASCULAR SYSTEM; ENDOCARDITIS; HEART; HEART VALVE BIOPROSTHESIS; HEART VALVE PROSTHESIS; HEART VALVE REPLACEMENT; HUMAN; REVIEW; RUPTURE; THERAPY; THROMBOEMBOLISM;

BIOMEDICAL ENGINEERING; HEART VALVE DISEASES; HEART VALVE PROSTHESIS; HUMAN; PROSTHESIS DESIGN; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0023229188     PISSN: 08860440     EISSN: 15408191     Source Type: Journal    
DOI: 10.1111/j.1540-8191.1987.tb00174.x     Document Type: Article

References (271)

1. Valvular heart disease: A perspective
2. The long‐term results of aortic valve replacement
3. Partial and complete prostheses in aortic insufficiency
4. Clinical experience with a ball‐valve prosthesis
5. Factors determining outcome of cardiac valve replacement
6. Significant patient‐related determinants of prosthetic valve performance
7. Reoperation on prosthetic heart valves. An analysis of risk factors in 552 patients
8. Early and late prognosis after reoperation for prosthetic valve replacement
9. The clinical life history of explanted prosthetic heart valves
10. Anatomic analysis of removed prosthetic heart valves: Causes of failure of 33 mechanical valves and 58 bioprostheses, 1980 to 1983
11. Early and late risk of aortic valve replacement. A 12 year concomitant comparison of the porcine bioprosthetic and tilting disc prosthetic aortic valves
12. Early and late risk of mitral valve repalcement. A 12‐year concomitant comparison of the porcine bioprosthetic and prosthetic disc mitral valves
13. Ten to fifteen year reassessment of the performance characteristics of the Starr‐Edwards Model 6120 mitral valve prosthesis
14. Performance characteristics of the Starr‐Edwards Model 1260 aortic valve prosthesis beyond ten years
15. Results of reoperation for primary tissue failure of porcine bioprostheses
16. Late causes of death after mitral replacement: Analysis of 36 cases
17. Pathologic anatomy of cardiac valve replacements: A study of 224 necropsy patients
18. Cardiac pathology after valve replacement with a tilting‐disk prosthesis (Björk‐Shiley type): A study of 46 necropsy patients and 49 Björk‐Shiley prostheses
19. Bioengineering aspects of heart valve replacement
20. Autopsy‐determined causes of death after cardiac valve replacement
21. Mitral replacement: Clinical experience with a ball‐valve prosthesis. Twenty‐five years later
22. Morphology of the heart in hypertrophy
23. Ten years' experience with the Björk‐Shiley tilting disc valve
24. Comparison of dysfunction with mechanical and porcine mitral valve prostheses
25. Clinical comparison of St. Jude and porcine aortic valve prostheses
26. Selection of a prosthetic heart valve
27. Long‐term comparative analysis of the Björk‐Shiley and Hancock valves implanted in 1975
28. Carbon in heart valve prostheses: Foundations and clinical performance
29. Sewing ring healing of cardiac valve prostheses
30. Biological factors affecting long‐term results of valvular heterografts
31. Pathology of the formalin‐treated heterograft porcine aortic valve in the mitral position
32. Pathology of xenografts in aortic valve replacement
33. Structural changes in glutraldehyde‐treated porcine heterografts used as substitute cardiac valves. Transmission and scanning electron microscope observations in 12 patients
34. Structure of bovine parietal pericardium and of unimplanted lonescu‐Shiley pericardial valvular bioprostheses
35. Collagen heterogeneity in pig heart valves
36. Collagen: Molecular diversity in the body's protein scaffold
37. Calcification of bovine pericardium used in cardiac valve bioprostheses. Implications for the mechanisms of bioprosthetic tissue mineralization
38. Type III collagen and probably not type I collagen aggregates platelets
39. Platelet adherence to bioprosthetic cardiac valves
40. Risk of haemorrhage associated with long term anticoagulant therapy
41. Bioprosthetic heart valve failure: Pathology and pathogenesis
42. Bioprosthetic heart valve pathology: Clinico‐pathologic features of valve failure and patho‐biology of calcification
43. Valve replacement in children. A fifteen‐year perspective
44. Five year follow‐up after valve replacement with the St. Jude Medical valve in infants and children
45. The problem of cardiac valve prostheses, anticoagulants, and pregnancy
46. Pregnancy after valve replacement with porcine xenograft prosthesis
47. Pregnancy in patients with a porcine valve bioprosthesis
48. Resolution of Heyde's syndrome of aortic stenosis and gastro‐intestinal bleeding after aortic valve replacement
49. Prosthetic heart valve replacement. Choice of prosthesis in a young, under‐developed population group
50. Twenty‐five years of heart valve substitutes: A review
51. Prosthetic heart valve replacements
52. Relative performance of prosthetic heart valves based on power measurements
53. In‐vitro pulsatile flow velocity and turbulent shear stress measurements in the vicinity of mechanical aortic heart valve prostheses
54. Bioengineering of mechanical and biologic heart valve substitutes
55. Prosthetic heart valves: A review
56. The problem of valve prosthesis‐patient mismatch
57. Hydraulic formula for calculation of the area of the stenotic mitral valve, other cardiac valves, and central circulatory shunts. I
58. Modification of the Gorlin equation for use with heart valve substitutes
59. In vitro hydrodynamic comparison of mitral valve bioprostheses
60. New generation tissue valves. Their in vitro function in the mitral position
61. In vitro hemodynamic characteristics of tissue bioprostheses in the aortic position
62. In vitro assessment of mitral valve prostheses
63. Regurgitation of prosthetic heart valves: Dependence on heart rate and cardiac output
64. Flow characteristics of four commonly used mechanical heart valves
65. Current status of cardiac valve replacement: Selection of a prosthesis and indication for operation
66. Quantitative anatomic analysis of “stent creep” of explanted Hancock standard and porcine bioprostheses used for cardiac valve replacement
67. Left ventricular outflow tract obstruction following mitral valve replacement: Effect of strut height and orientation
68. Durability of prosthetic heart valves
69. Surface studies of carbon for prosthetic application
70. Fatigue‐induced failure of the Ionescu‐Shiley pericardial xenograft in the mitral position
71. Surgical pathology of removed natural and prosthetic heart valves
72. Factors associated with periprosthetic leakage following primary mitral valve replacement: With special consideration of the suture technique
73. Thromboembolic complications of current cardiac valvular prostheses
74. Thromboembolism in heart valve replacement
75. Death and other time‐related events after valve replacement
76. On the mechanism of thrombosis
77. The Starr‐Edwards aortic ball valve: Flow characteristics, thrombus formation, and tissue overgrowth
78. The Björk‐Shiley aortic prosthesis: Flow characteristics, thrombus formation and tissue overgrowth
79. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: The Framingham study
80. Mortality in an insured population with atrial fibrillation
81. Pathological substrates of thrombus formation after heart valve replacement with the Hancock bioprosthesis
82. Acute thrombotic obstruction with disc valve prostheses: Diagnostic considerations and fibrinolytic treatment
83. Fibrinolytic therapy of St. Jude valve thrombosis under guidance of digital cinefluoroscopy
84. Fibrinolytic treatment in thrombotic obstruction of a tilting disc prosthesis
85. Fate of thromboectomized Björk‐Shiley valve. A long‐term cinefluorscopic, echocardiographic, and hemodynamic evaluation
86. Systemic thromboembolism in valvular heart disease and prosthetic heart valves
87. Studies of platelet and fibrinogen kinetics in patients with prosthetic heart valves
88. Platelet interactions with biomaterials and artificial devices
89. Noninvasive radioisotopic technique for detection of platelet deposition in mitral valve prostheses and quantitation of visceral microembolism in dogs
90. Quantitation of platelet and fibronogen‐fibrin deposition on components of tissue valves (Ionescu‐Shiley) in calves
91. Elevation of plasma B‐thromboglobulin in patients with prosthetic cardiac valves
92. Platelet survival in patients with substitute heart valve
93. Platelet suppressant therapy in patients with prosthetic cardiac valves. Relationship of clinical effectiveness to alteration of platelet survival time
94. Antiplatelet drugs in the management of patients with thrombotic disorders
95. Clinical trials evaluating platelet‐modifying drugs in patients with atherosclerotic cardiovascular disease and thrombosis
96. The hypercoagulable states
97. Risks of anticoagulant therapy in pregnant women with artifical heart valves
98. Prosthetic valve infective endocarditis
99. Evaluation and management of prosthetic valve endocarditis
100. Prosthetic valve endocarditis
101. Prosthetic valve endocarditis
102. Risk factors for the development of prosthetic valve endocarditis
103. Comparison of bioprosthetic and mechanical valve replacement for active endocarditis
104. Prosthetic valve endocarditis. Clinicopathologic analysis of 22 necropsy patients with comparison of observations in 74 necropsy patients with acitve infective endocarditis involving natural left‐sided cardiac valves
105. A clinic‐opathologic study of prosthetic valve endocarditis in 22 patients: Morphologic basis for diagnosis and therapy
106. Infection within a degenerated Starr‐Edwards silicone rubber poppet in the aortic valve position
107. Surgical treatment of prosthetic valve endocarditis
108. Prosthetic valve endocarditis. Analysis of factors affecting outcome of therapy
109. Pathological study of infective endocarditis on Hancock porcine bioprostheses
110. Infection of glutaraldehyde‐preserved porcine valve heterografts
111. Long‐term failure rate and morphologic correlations in porcine bioprosthetic heart valves
112. Endocarditis in patients with bioprostheses: Pathology and clinical correlations
113. Bacterial associated porcine heterograft heart valve calcification
114. Prosthetic valve endocarditis. Comparison of heterograft tissue valves and mechanical valves
115. Biomaterials‐associated infection, neoplasia and calcification: Clinicopathologic features and pathophysiologic concepts
116. Pathology of cardiac valve replacement
117. Sustained release of gentamicin from prosthetic heart valves
118. Implantation of antibiotic‐ releasing carriers for treatment of recurrent prosthetic endocarditis
119. Staphylococcus epidermidis causing prosthetic valve endocarditis: Microbiologic and clinical observations as guides to therapy
120. Bacterial study of pyogenic infections of dental origin
121. Antibiotic susceptibility of bacteria isolated from oral infection
122. Aortic ball variance: Diagnosis and treatment
123. Implications of late morphology of Braunwald‐Cutter mitral heart valve prostheses
124. Durability of pyrolytic carbon‐containing heart valve prostheses
125. Changes in the durability of silicone rubber in ball‐valve prostheses
126. Formaldehyde‐ versus glutaraldehyde‐processed porcine bioprostheses in the aortic valve position: Long‐term follow‐up
127. Strut fracture and disc embolization in Björk‐Shiley mitral valve prostheses: Diagnosis and management
128. Lipids in silicons rubber valve prostheses after human implantation
129. Prophylactic replacement of a Starr‐Edwards Model 1000 aortic valve prosthesis in place for 20 years
130. Stuck aortic poppet. A hazard of close‐clearance cloth covered prosthetic aortic valves
131. Complications in patients with cloth‐covered Starr‐Edwards prostheses
132. Cardiac pathology after valve replacement by disc prosthesis. A study of 61 necropsy patients
133. The pathology of wear in the Beall Model 104 heart valve prosthesis
134. Occluder disruption of Wada‐Cutter valve prostheses
135. Detection of ball variance in prosthetic heart valves by liver biopsy
136. Wear in Björk‐Shiley heart valve prostheses recovered at necropsy or operation
137. Metal wear in Lillehel‐Kaster heart valve prostheses
138. Fatal failure of a prosthetic mitral valve
139. Mechanical valve occluder dislodgement
140. Spontaneous embolization of a St. Jude prosthetic mitral valve leaflet
141. Strut fracture and disc embolization in Björk‐Shiley mitral valve prostheses: Diagnosis and management
142. Experience with outlet strut fracture of the Björk‐Shiley convexoconcave mitral valve prosthesis
143. Mechanical failure of the Björk‐Shiley valve. Incidence, clinical presentation, and management
144. Complications of convexo‐concave heart valves
145. Mechanical failures in in‐vivo and in‐vitro studies of pneumatic total artificial hearts
146. Clinical use of the total artificial heart
147. The durability of porcine xenograft valves and conduits in children
148. Fate of left‐sided cardiac bioprosthesis valves in children
149. Six‐ to ten‐year follow‐up of patients with the Hancock cardiac bioprosthesis
150. Comparison of long‐term results of Carpentier‐Edwards and Hancock bioprosthetic valves
151. Primary tissue valve degeneration in glutaraldehyde‐preserved porcine bioprostheses: Hancock I versus Carpentier‐Edwards at 4‐ to 7‐years' follow‐up
152. Noninvasive evaluation of normal and abnormal prosthetic valve function
153. Doppler echocardiographic evaluation of patients with porcine mitral valves
154. Doppler echocardiographic evaluation of Hancock and Björk‐Shiley prosthetic valves
155. Frequency spectra of the first heart sound and of the aortic component of the second heart sound in patients with degnerated porcine bioprosthetic valves
156. Structure and classification of cuspal tears and perforations in porcine bioprosthetic cardiac valves implanted in patients
157. Calcific deposits in porcine bioprostheses: Structure and pathogenesis
158. Ultrastructural substrates of dystrophic calcification in porcine bioprosthetic valve failure
159. Clinical durability of the pericardial xenograft valve: Ten years' experience with mitral replacement
160. Ionescu‐Shiley pericardial xenografts: Follow‐up of up to 6 years
161. Valve failure with the Ionescu‐ Shiley bovine pericardial bioprosthesis: Analysis of 2680 patients
162. Comparative study of primary tissue valve failure between Ionescu‐Shiley pericardial and Hancock porcine valves in the aortic position
163. Long‐term follow‐up of the Ionescu‐Shiley mitral pericardial xenograft
164. Long‐term durability of the pericardial valve
165. Ionescu‐Shiley bovine pericardial bioprostheses: Clinical results in 2,701 patients
166. An 8‐year experience with the standard Ionescu‐Shiley pericardial valve in the aortic position
167. Causes of failure and pathologic findings in surgically removed bovine pericardial heart valve bioprostheses
168. Pathologic evaluation of a unileaflet pericardial bioprosthesis after implantation as a tricuspid and mitral valve replacements in sheep
169. The Meadox unicusp pericardial bioprosthetic heart valve: New concept
170. Pericardial heterografts. Toward quality control of the mechanical properties of glutaraldehyde‐fixed leaflets
171. Certain aspects of blood interfacial phenomena. Red blood cells
172. Renal hemosiderosis in patients with prosthetic aortic valves
173. Cholelithiasis: A frequent complication of artificial heart valve replacement
174. Chronic intravascular hemolysis after aortic valve replacement with Ionescu‐Shiley xenograft: Comparative study with Björk‐Shiley prostheses
175. Late clinical problems with Beall Model 103 and 104 mitral valve prostheses: Hemolysis and valve wear
176. Complications due to cloth wear in cloth‐covered Starr‐Edwards aortic and mitral valve prosthesis—And their management
177. Acute intravascular hemolysis indicating thrombosis of Björk‐Shiley aortic prosthesis
178. Severe hemolytic anemia in patients with a porcine aortic valve prosthesis
179. Hemolytic anemia following insertion of Ionescu‐Shiley mitral valve bioprostheses
180. Complications of cardiac valve replacement: Characteristic abnormalities of prostheses pertaining to any or specific site
181. Clinical and necropsy observations early after simultaneous replacement of the mitral and aortic valves
182. Malfunction of mitral Björk‐Shiley prosthetic valve due to septal interference
183. Left ventricular outflow obstruction after aortic valve replacement: Detection with continuous wave doppler ultrasound recording
184. Extrinsic obstruction of the Björk‐Shiley valve in the mitral position
185. Acute immobilization of the disc in the Björk‐Shiley aortic tilting disc valve prosthesis
186. A precaution when using the St. Jude Medical prosthesis in the aortic valve position
187. Fatal bioprosthetic regurgitation immediately after mitral and tricuspid valve replacement with Ionescu‐Shiley bioprostheses
188. Cuspal perforations caused by long suture ends in implanted bioprosthetic valves
189. Malfunction of a St. Jude medical heart valve in mitral position
190. Intermittent aortic regurgitation following aortic valve replacement with the Hall‐Kaster prosthesis
191. Structural changes in glutaraldehyde‐treated porcine heterografts used as substitute cardiac valves
192. Porcine aortic vs. bovine pericardial valves: A morphologic study of the Xenomedica and Mitroflow bioprostheses
193. Occurrence and significance of endothelial cells in implanted porcine bioprosthetic valves
194. Intracuspal hematomas in implanted porcine valvular bioprostheses
195. Whipple's disease in the porcine leaflets of a Carpentier‐Edwards prosthetic mitral valve
196. Porcine heterograft valve replacement in carcinoid heart disease
197. Valve failure in seventy‐two frame supported autologous fascia lata mitral valves. Two‐year follow‐up
198. Structural alterations in tissue cardiac valves implanted in patients and in calves
199. Morphologic observations on heart valve prostheses made of fascia lata
200. Replacement of the aortic valve with molded autogenous grafts grown in response to implanted silastic
201. Long‐term assessment of aortic valve replacement with autologous pulmonary valve
202. Patient status 10 or more years after “fresh” homograft replacement of the aortic valve
203. Homograft aortic valve replacement: Seven years' experience with antibiotic‐treated valves
204. Fifteen years' experience with the aortic homograft: The conduit of choice for right ventricular outflow tract reconstruction
205. Aortic valve homografts in the surgical treatment of complex cardiac malformation
206. Homograft replacement of the aortic valve. A critical review
207. Pathology of grafted heart valves
208. The immunologic response to heterotopic allovital aortic valve transplants in presensitized and nonsensitized recipients
209. Cardiothoracic surgery in the Antipodes
210. Long‐term results after aortic valve replacement with preserved aortic homografts
211. Aortic valve replacement with preserved aortic valve homografts
212. Aortic valve replacement with frozen irradiated homografts. Long‐term evaluation
213. The pathology of chemically‐sterilized human heart valve allografts
214. Histopathology of “fresh” human aortic valve allografts
215. Pathology of antibiotic‐treated human heart valve allografts
216. Histological assessment of orthotopic aortic valve leaflet allografts: It role in selecting graft pre‐treatment
217. Morphology of heart valves preserved by liquid nitrogen freezing
218. Graft detachment, a cause of incompetence in stent‐mounted aortic valve allografts
219. Homograft aortic root replacment for complicated prosthetic valve endocarditis
220. Fatigue‐induced damage in glutaraldehyde‐preserved heart valve tissue
221. Continuing improvements in valvular bioprostheses
222. Bicuspid mitral bioprosthesis
223. Bioprosthetic valvular failure. Clinical and pathologic observations in an experimental animal model
224. Onset and progression of experimental bioprosthetic heart valve calcification
225. Porcine bioprosthetic valve calcification in bovine left ventricle‐aorta shunts: Studies of the deposition of vitamin K‐dependent proteins
226. Calcification of cardiac valve bioprostheses. Biochemical, histologic and ultrastructural observations in a subcutaneous implantation model system
227. Biologic determinants of dystrophic calcification and osteocalcin deposition in glutaraldehyde‐preserved porcine aortic valve leaflets implanted subcutaneously in rats
228. Pathophysiology of bioprosthetic heart valve calcification
229. Calcification of subcutaneously implanted type I collagen sponges. Effects of formaldehyde and glutaraldehyde pretreatments
230. Role of mechanical stress in calcification of aortic bioprosthetic valves
231. Carboxylated calcium‐binding proteins and vitamin K
232. Effect of warfarin on calcification of spontaneously degenerated porcine bioprosthetic valves
233. Calcification inside artificial hearts: Inhibition by warfarin sodium
234. LVAD mineralization of gammacarboxyglutamic acid containing proteins in normal and pathologically mineralized tissue
235. Fate of a second porcine bioprosthetic valve
236. Porcine xenograft valve failure in children. An immunologic response
237. Mechanism of calcification of porcine bioprosthetic aortic valve cusps: Role of T‐lymphocytes
238. The role of glutaraldehyde‐induced crosslinks in calcification of bovine pericardium used in cardiac valve bioprostheses
239. Anticalcification effect of glutaraldehyde‐preserved valve tissue stored for increasing time in glutaraldehyde
240. Myocardial ischemia revisited. The osmolar load, membrane damage, and reperfusion
241. Calcification of cardiac valve bioprostheses. Host and implant factors
242. Bioprosthetic heart valve calcification: Clinical features, patho‐biology, and prospects for prevention
243. Inhibition by diphosphonate compounds of calcification of porcine bioprosthetic heart valve cusps implanted subcutaneously in rats
244. Inhibition of calcification of bioprosthetic heart valves by local controlled‐released diphosphonate
245. Prevention of intrinsic calcification in porcine and bovine xenograft materials
246. Modification by the Hancock T6 process of calcification of bioprosthetic cardiac valves implanted in sheep
247. Current concepts of the physiology and biochemistry of calcification
248. Synthesis and characterization of phosphocitric acid, a potent inhbitor of hydroxyapatite crystal growth
249. Calcification inhibitors in rat and human serum and plasma
250. Phosphocitrate and its analogue N‐sulpho‐2‐amino tricarballylate inhibit aortic calcification
251. Comparative clinical results with Omniscience (STMl), Medtronic‐Hall, and Björk‐Shiley convexo‐concave (70 degrees) prostheses. I. Mitral valve replacement
252. Six years of experience with the St. Jude Medical valvular prosthesis
253. A late evaluation of flexible Teflon prostheses utilized for total aortic valve replacement
254. Cardiac pathology after valve replacement using Hufnagel trileaflet prostheses: A study of 20 necropsy patients
255. Function of expanded polytetrafluoroethylene laminated trileaflet valves in animals
256. A polyurethane trileaflet cardiac valve prosthesis: In vitro and in vivo studies
257. Development of seamless tri‐leaflet valves
258. Hexsyn trileaflet valve: Application to temporary blood pumps
259. Canine model for long‐term evaluation of prosthetic mitral valves
260. Pathology of cardiovascular prostheses including coronary artery bypass and vascular grafts
261. A guide to radiographic identification of prosthetic heart valves: An addendum
262. Calcification of porcine prosthetic heart valves: A radiographic and light microscopic study
263. Mechanisms of arterial graft failure. 1. Role of cellular proliferation in early healing of PTFE prostheses
264. Optical methods for the nondestructive evaluation of collagen morphology in bioprosthetic heart valves
265. Surface morphology of degenerated porcine bioprosthetic valves four to seven years following implantation